IL254153A0 - Pharmaceutical compositions in salt form of semicarbazide-sensitive amine oxidase inhibitor (ssao) - Google Patents

Pharmaceutical compositions in salt form of semicarbazide-sensitive amine oxidase inhibitor (ssao)

Info

Publication number
IL254153A0
IL254153A0 IL254153A IL25415317A IL254153A0 IL 254153 A0 IL254153 A0 IL 254153A0 IL 254153 A IL254153 A IL 254153A IL 25415317 A IL25415317 A IL 25415317A IL 254153 A0 IL254153 A0 IL 254153A0
Authority
IL
Israel
Prior art keywords
ssao
semicarbazide
inhibitor
salt forms
pharmaceutical salt
Prior art date
Application number
IL254153A
Other languages
English (en)
Hebrew (he)
Inventor
Edward Savory
Michael Higginbottom
Original Assignee
Proximagen Ltd
Edward Savory
Michael Higginbottom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd, Edward Savory, Michael Higginbottom filed Critical Proximagen Ltd
Publication of IL254153A0 publication Critical patent/IL254153A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL254153A 2015-04-24 2017-08-24 Pharmaceutical compositions in salt form of semicarbazide-sensitive amine oxidase inhibitor (ssao) IL254153A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507031.1A GB201507031D0 (en) 2015-04-24 2015-04-24 New pharmaceutical salt forms
PCT/GB2016/051119 WO2016170351A1 (en) 2015-04-24 2016-04-22 Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Publications (1)

Publication Number Publication Date
IL254153A0 true IL254153A0 (en) 2017-10-31

Family

ID=53488629

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254153A IL254153A0 (en) 2015-04-24 2017-08-24 Pharmaceutical compositions in salt form of semicarbazide-sensitive amine oxidase inhibitor (ssao)

Country Status (19)

Country Link
US (1) US10316034B2 (enExample)
EP (1) EP3286190B1 (enExample)
JP (2) JP2018513189A (enExample)
KR (1) KR20170139045A (enExample)
CN (2) CN107531702A (enExample)
AR (1) AR104360A1 (enExample)
AU (1) AU2016251707B2 (enExample)
BR (1) BR112017020016A2 (enExample)
CA (1) CA2979144A1 (enExample)
DK (1) DK3286190T3 (enExample)
EA (1) EA035668B1 (enExample)
ES (1) ES2804155T3 (enExample)
GB (1) GB201507031D0 (enExample)
HU (1) HUE049985T2 (enExample)
IL (1) IL254153A0 (enExample)
MX (1) MX2017013049A (enExample)
PT (1) PT3286190T (enExample)
SG (1) SG11201707867WA (enExample)
WO (1) WO2016170351A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201618029D0 (en) 2016-10-25 2016-12-07 Proximagen Ltd New process
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) * 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
SE0004101D0 (sv) 2000-11-09 2000-11-09 Pharmacia Ab New use
AU2002214505A1 (en) * 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
WO2005082343A2 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US8633318B2 (en) * 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
MX2011002581A (es) * 2008-09-16 2011-04-07 Proximagen Ltd Compuestos nuevos i.
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
CN103889983B (zh) * 2011-09-14 2015-12-09 普罗克西梅根有限公司 酶抑制剂化合物
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain

Also Published As

Publication number Publication date
CN107531702A (zh) 2018-01-02
CA2979144A1 (en) 2016-10-27
JP2018513189A (ja) 2018-05-24
SG11201707867WA (en) 2017-11-29
HUE049985T2 (hu) 2020-11-30
ES2804155T3 (es) 2021-02-04
AR104360A1 (es) 2017-07-12
AU2016251707B2 (en) 2020-02-20
US10316034B2 (en) 2019-06-11
DK3286190T3 (da) 2020-07-13
WO2016170351A1 (en) 2016-10-27
EA201792121A1 (ru) 2018-03-30
PT3286190T (pt) 2020-07-09
EA035668B1 (ru) 2020-07-23
EP3286190B1 (en) 2020-06-03
GB201507031D0 (en) 2015-06-10
BR112017020016A2 (pt) 2018-06-19
US20180111928A1 (en) 2018-04-26
HK1249906A1 (en) 2018-11-16
CN112851669A (zh) 2021-05-28
MX2017013049A (es) 2017-12-08
AU2016251707A1 (en) 2017-10-05
JP2021073256A (ja) 2021-05-13
EP3286190A1 (en) 2018-02-28
KR20170139045A (ko) 2017-12-18

Similar Documents

Publication Publication Date Title
ZA201901097B (en) Amino pyrimidine ssao inhibitors
IL281939A (en) VAP-1 inhibitors
PT3626699T (pt) Inibidor de ssao
EP3344624B8 (en) Tyk2 inhibitors and uses thereof
ZA201604272B (en) Inhibitors of glutaminase
HUE070538T2 (hu) Egy LSD1 inhibitor sói
EP3262049A4 (en) Tyk2 inhibitors and uses thereof
IL268625A (en) Amino pyrimidine compounds used as SSAO inhibitors
SG11201708034SA (en) Methods of administering glutaminase inhibitors
CA3285092A1 (en) Salts of pi3k inhibitor and processes for their preparation
IL257061A (en) Inhibitors of ezh2
ZA201808345B (en) Capsules comprising benzylpropargylethers for use as nitrification inhibitors
GB201615282D0 (en) Tankyrase inhibitors
EP3405477C0 (en) TRANSGLUTAMINASE INHIBITORS
EP3310374A4 (en) GLUTATHION FORMULATION AND METHOD OF USE
IL281815A (en) Inhibitors of vap-1
IL254266B (en) Glucosylceramide synthase inhibitors for the treatment of diseases
SG11201707867WA (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)
IL254154A0 (en) A crystalline compound as an inhibitor of the enzyme semicarbazide-sensitive amine oxidase (ssao)
EP3268011A4 (en) DEK PROTEIN INHIBITORS AND ASSOCIATED METHODS
HK40010000A (en) Amino pyrimidine ssao inhibitors
EP3271542A4 (en) Self positioning floating platform and method of use
AU2015902765A0 (en) Novel aminopeptidase inhibitors and methods of use
AU2015901351A0 (en) Haloallylamine inhibitors of amine oxidases and uses thereof
AU2015903172A0 (en) Inhibitors of necroptosis